Lindsey Rolfe

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Elizabeth M. Swisher, Kevin Lin, Amit M. Oza et al. · The Lancet Oncology · 2016 · 1.2K citations · Full text

Medicine, Pharmacology, Pathology +6

Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer

Lecia V. Sequist, Jean‐Charles Soria, Jonathan W. Goldman et al. · New England Journal of Medicine · 2015 · 660 citations · Full text

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

Karen L. Reckamp, Vladislava O. Melnikova, Chris Karlovich et al. · Journal of Thoracic Oncology · 2016 · 283 citations · Full text

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2

Amit M. Oza, Anna V. Tinker, Ana Oaknin et al. · Gynecologic Oncology · 2017 · 272 citations · Full text

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors

Rebecca Kristeleit, Geoffrey I. Shapiro, Howard A. Burris et al. · Clinical Cancer Research · 2017 · 236 citations